AbbVie Advances Clinical Pipeline With IPF and Aesthetics Trial Updates
AbbVie reported progress on two clinical studies: a Phase 2a trial of ABBV-142 for idiopathic pulmonary fibrosis now recruiting patients, and completion of a JUVÉDERM VOLITE study for facial skin quality improvement.
AbbVie is running a Phase 2a multicenter platform study of investigational products in adults with idiopathic pulmonary fibrosis (IPF), aimed at checking safety, tolerability, and early signs that the drugs can slow or improve disease activity. The trial is now in the recruiting phase, reflecting active site and patient startup, with the latest update filed on Feb. 19, 2026.
The main drug in the first part of the study, ABBV-142, is an experimental pill designed to treat IPF by targeting disease pathways that drive lung scarring. It is compared with a matching placebo to see if it can reduce symptoms and lung damage while keeping side effects manageable over a one-year treatment period.
The study is interventional and randomized, meaning patients are assigned by chance to ABBV-142 or placebo in parallel groups. It is also double-blind and uses a placebo control, so neither patients nor doctors know who gets active treatment. The trial began enrolling after its initial submission on Nov. 14, 2025.
Separately, AbbVie completed a multicenter, evaluator-blinded, randomized, no-treatment controlled study of the effectiveness and safety of JUVÉDERM VOLITE injectable gel for the improvement in skin quality. The overall status is now listed as completed, with the most recent update filed on Feb. 16, 2026, signaling that data cleaning and regulatory-facing documentation are likely underway.
JUVÉDERM VOLITE is an intradermal injectable gel filler designed to improve fine lines, hydration, and overall skin radiance in adults with visible skin quality deficits. Participants were followed for 12 months after a single initial injection, with optional touch-up. The no-treatment control group could cross over to receive VOLITE after two months. The study was first submitted on Aug. 7, 2024.
The IPF field already includes players such as Roche, Boehringer Ingelheim, and others with approved therapies that slow but do not stop disease. The premium facial aesthetics space remains competitive, with strong players like Allergan Aesthetics (now part of AbbVie), Galderma, and other filler makers.
AbbVie reported net revenues of $61,160 million for 2025, reflecting an 8.6% increase from the previous year, driven by strong market share uptake and market growth across key products. The immunology segment, including Skyrizi and Rinvoq, showed significant growth, with Skyrizi's total revenue increasing by 49.9% and Rinvoq's by 39.1% compared to the previous year. However, Humira's revenue declined by 49.5% due to biosimilar competition.
The company is advancing its R&D pipeline with significant investments in immunology, neuroscience, oncology, and aesthetics. AbbVie anticipates several regulatory submissions, approvals, and data readouts from key clinical trials in the next 12 months. The company is committed to a $100 billion investment in U.S.-based R&D and capital projects over the next decade, including manufacturing expansions.